Psychopathological symptoms in the long-term course of an acute psychosis after intake of mefloquine;PSYCHOPATHOLOGISCHE PHANOMENE IM LANGZEITVERLAUF EINER AKUTEN PSYCHOSE NACH MEFLOQUINPROPHYLAXE (LARIAM®)

Nervenarzt

Volumn 67, Issue 5, 1996, Pages 404-406

  Meszaros, K ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

mefloquine; psychosis

Indexed keywords

AMITRIPTYLINE; CHLORPROTHIXENE; CLOMIPRAMINE; FLUPHENAZINE; MEFLOQUINE; OXAZEPAM; THIORIDAZINE; ANTIMALARIAL AGENT;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALARIA; MALE; PSYCHOSIS; FOLLOW UP; PSYCHOLOGICAL ASPECT; RISK FACTOR; TRAVEL;

ADULT; ANTIMALARIALS; FOLLOW-UP STUDIES; HUMANS; MALARIA; MALE; MEFLOQUINE; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; TRAVEL;

EID: 0030133172     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bern JL, Kerr L, Stürchler D (1992) Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 95: 167-179
2. Bernhard J, Lecamus J, Sarrouy J (1989) Encephalopathie toxique a la mefloquine: a propos de 3 observations. Med Armees 17: 209-211
3. Besser R, Krämer G (1991) Verdacht auf anfallfördernde Wirkung von Mefloquin (LariamR). Nervenarzt 62: 760-761
4. Björkman A (1989) Acute psychosis following mefloquine prophylaxis. Lancet 2: 865
5. Caillon E, Schmitt L, Moron P (1992) Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 149: 712
6. De Souza JM (1982) A phase II clinical trial of mefloquine in Brazilian male subjects. Bull WHO 61: 815-820
7. Fish D, Espir M (1988) Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. Br Med J 297: 526-527
8. Folkerts H, Kuhs H (1992) Psychotische Episode infolge Malariaprophylaxe mit Mefloquin. Nervenarzt 63: 300-302
9. Fröscher W, Hägele H (1989) Verdacht auf anfallfördernde Wirkung von Chloroquin (Resochin R). Nervenarzt 60: 762-763
10. Garcia C (1994) Psychopathologie der Malaria. Nervenarzt 65: 156-162
11. Harinasuta T, Bunnag D, Wernsdorfer WH (1983) A phase II clinical trial of mefloquine in patients with chloroquine resistant falciparum malaria in Thailand. Bull WHO 61: 299-305
12. Jallon P (1988) Use of mefloquine in epileptic patients. J Neurol Neurosurg Psychiatry 51: 732
13. Kerr L (1992) Adverse effects from spontanous reporting associated with LariamR (mefloquine). Hoffmann-La Roche
14. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8-19
15. Kiel FW (1964) Chloroquine suicide. JAMA 190: 398-400
16. Lapras J, Vighetto A, Trillet M, Garin JP (1989) Trouble transitoire de memoire au decours d'un acces palustre. Presse Med 18: 776
17. Moran JS, Bernard KW, Greenberg AE, Patchen L, Waterman S (1987) Failure of chloroquine treatment to prevent malaria in Americans in West Africa. JAMA 258: 2376-2377
18. Olbrich R (1987) Die Verletzbarkeit des Schizophrenen: J. Zubins Konzept der Vulnerabilität. Nervenarzt 58: 65-71
19. Patchen LC, Campbell CC, Williams SB (1989) Neurologic reactions after therapeutic dose of mefloquine. N Engl J Med 321: 1415-1416
20. Propping P (1989) Psychiatrische Genetik. Befunde und Konzepte. Springer, Berlin Heidelberg New York
21. Rouveix B, Bricaire F, Michon C, Franssen G, Lebras J, Bernard J, Ajana F, Vienne JL (1989) Mefloquine and an acute brain syndrome. Ann Intern Med 110: 577-578
22. Singh K, Shanks D, Wilde H (1991) Seizures after Mefloquine. Ann Intern Med 11: 994
23. Steffen R, Heusser R, Machler R (1990) Malaria chemoprophylaxis in European tourists visiting tropical Africa: use, adverse reactions, and efficacy. Bull WHO 68: 313-322
24. Stürchler D, Handschin J, Kaiser D, Kerr L, Mittelholzer ML, Reber R, Fernex M (1990) Neuro psychiatric side effects of mefloquine. N Engl J Med 322: 1752-1753
25. Stuiver PC, Ligthelm RJ, Goud TJ (1989) Acute psychosis after mefloquine. Lancet 2: 282
26. Torrey EF (1968) Chloroquine seizures. Report of four cases. JAMA 204: 867-870
27. Weinke T, Trautmann M, Held T (1991) Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45: 86-91
28. World Health Organisation (1984) Advances in malaria chemotherapy. WHO Tech Rep Ser 711
29. World Health Organisation (1989) Prophylactic and therapeutic use of mefloquine. Weekly Epidemiol Rec 64: 247-248
30. World Health Organisation (1991) Review of central nervous system adverse events related to antimalarial drug mefloquine (1985-1990), p 1063
31. Zubin J, Spring B (1977) Vulnerability - a new view of schizophrenia. J Abnorm Psychol 86: 103-126
32. Zubin J, Steinhauer SR (1981) How to break the logjam in schizophrenia: a look beyond genetics. J Nerv Ment Dis 169: 477-492
33. Zubin J, Magaziner J, Steinhauer SR (1983) The metamorphosis of schizophrenia: from chronicity to vulnerability. Psychol Med 13: 551-571